![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 50, 48270-48275, December 13, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
,
,
, and
From the MUC2 is one of the major components of
mucins that provide a protective barrier between epithelial
surfaces and the gut lumen. We investigated possible alterations of
MUC2 gene expression by p53 and
p21Sdi1/Waf1/Cip1 in a human colon cancer cell line, DLD-1,
establishing subclones in which a tetracycline-regulatable promoter
controls exogenous p53 and p21 expression. MUC2 mRNA
more significantly increased in response to p53 than to p21.
Unexpectedly, MUC2 expression was also induced in human
osteosarcoma cells, U-2OS and Saos-2, by exogenous p53. We next
performed a reporter assay to test the direct regulation of
MUC2 gene expression by p53. Deletion and mutagenesis of
the MUC2 promoter region showed that it contains two sites
for transactivation by p53. Furthermore, an electrophoretic mobility
shift assay indicated that p53 binds to those elements. We analyzed
MUC2 expression in other cell types possessing a functional p53 after exposure to various forms of stress. In MCF7 breast cancer
and A427 lung cancer cells, MUC2 expression was increased along with the endogenous p53 level by actinomycin D, UVC, and x-ray,
but not in RERF-LC-MS lung cancer cells carrying a mutated p53. These
results suggest that p53 directly activates the MUC2 gene
in many cell types.
Second Department of Biochemistry and
¶ First Department of Internal Medicine, Hirosaki University
School of Medicine, Zaifucho 5, Hirosaki, Aomori 036-8562, Japan and
Center for Education and Research of Lifelong Learning,
Hirosaki University, Bunkyo-cho 1, Hirosaki,
Aomori 036-8560, Japan
This article has been cited by other articles:
![]() |
R. Hokari, H. Lee, S. C. Crawley, S. C. Yang, J. R. Gum Jr, S. Miura, and Y. S. Kim Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1 Am J Physiol Gastrointest Liver Physiol, November 1, 2005; 289(5): G949 - G959. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Levi, D S Klimstra, N V Adsay, A Andea, and O Basturk MUC1 and MUC2 in pancreatic neoplasia J. Clin. Pathol., May 1, 2004; 57(5): 456 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Abroun, H. Ishikawa, N. Tsuyama, S. Liu, F.-J. Li, K.-i. Otsuyama, X. Zheng, M. Obata, and M. M. Kawano Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor {alpha} Blood, March 15, 2004; 103(6): 2291 - 2298. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Mesquita, N. Jonckheere, R. Almeida, M.-P. Ducourouble, J. Serpa, E. Silva, P. Pigny, F. S. Silva, C. Reis, D. Silberg, et al. Human MUC2 Mucin Gene Is Transcriptionally Regulated by Cdx Homeodomain Proteins in Gastrointestinal Carcinoma Cell Lines J. Biol. Chem., December 19, 2003; 278(51): 51549 - 51556. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Itoh, C. O'Shea, and S. Linn Impaired Regulation of Tumor Suppressor p53 Caused by Mutations in the Xeroderma Pigmentosum DDB2 Gene: Mutual Regulatory Interactions between p48DDB2 and p53 Mol. Cell. Biol., November 1, 2003; 23(21): 7540 - 7553. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |